UPDATED INFORMATION – March 10, 2022 Further to the Health Canada communication below, issued on June 15, 2021, while initial estimates of supply and demand forecasted that the global shortage could impact Canada’s supply in early 2022, careful allocation of product supply throughout 2021 has successfully prevented a shortage in Canada to date. Additional supplies of pentobarbital sodium have now been secured, and it is expected that there should be adequate supply to cover normal Canadian demand in 2022. In November 2021, Health Canada also approved a new euthanasia product containing pentobarbital sodium for the Canadian market . The Canadian Veterinary Medical Association continues to make available, through their website, Guidance for Veterinarians on Euthanasia Methods that Do Not Include Pentobarbital Sodium . The current document can be accessed by CVMA members as well as non-members on the National Issues page of the Policy & Advocacy section of the CVMA website, canadianveterinarians.net . This is a live document that will be updated as new information becomes available. June 15, 2021 Due to a global shortage, availability in Canada of currently licensed euthanasia products containing pentobarbital sodium, manufactured by Vétoquinol and Rafter8 Products Inc., is expected to impact the existing supply in mid- to late 2021 and continue until mid-2022. Health Canada is working in collaboration with CAHI (the national association representing industry), the CVMA, drug manufacturers, importers and distributors to mitigate the impact on the veterinary health system and Canadians requiring end-of-life care for their animals/pets.
RecallTracker